ASRS '26: SOL-1 and TRUCKEE at 4.5 Years

Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD.

And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.